Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2019

View Archived Issues

Decreased inhibition, but no hyperexcitation, in multiple autism models

The Model T of CAR T cells?

Novo Nordisk initiates phase II study of NNC-0174-0833 for weight management

Serum CIRP as novel biomarker for monitoring disease activity in alopecia areata

Exosome therapy for hair loss shows promise

Eli Lilly studies LY-3375880 in phase II trial for moderate to severe atopic dermatitis

BARDA supports development of vaccine against Marburg virus infection

PPT1 inhibition through DC-661 compound shows antitumoral effects

SpringWorks Therapeutics initiates phase III study of nirogacestat

In gut, skin fungus may contribute to IBD

Tyme Technologies adds preclinical candidate to pipeline

Novel noninvasive rodent model of alopecia areata described

New variant of genetic mutation in the ANTXR2 gene found to be associated with hyaline fibromatosis

CBT-509 demonstrates promising efficacy in preclinical cancer models

Pirfenidone partially reverses severe pulmonary arterial hypertension in rat models

Novel tumor microenvironment system based on a 3D human co-culture with patient-derived tumor cells

GlaxoSmithKline and BioVersys divulge new antimycobacterials

Idorsia Pharmaceuticals discloses IDO1 and/or TDO inhibitors

Roche discloses metabotropic glutamate mGlu4 receptor PAMs

Agios Pharmaceuticals patents PKLR activators

European approval for Tecentriq with Avastin and chemotherapy for metastatic non-squamous NSCLC

Pfizer identifies TYK2 inhibitors

HOXC6 gene expression linked to cervical cancer progression

Helsinn opens phase III program with anamorelin to treat weight loss and anorexia in NSCLC cachexia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...